Fulgent Genetics (FLGT) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Fulgent Genetics (FLGT) has outperformed Myriad Genetics (MYGN) over the past year, losing 8.8% versus a loss of 45.0%. Over five years, FLGT leads with a -73.3% price change compared with -86.8% for MYGN. Fulgent Genetics is the larger company by market cap ($580.2 million vs $399.8 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FLGT | MYGN |
|---|---|---|
| Share price | $21.09 | $4.18 |
| Market cap | $580.16M | $399.82M |
| 1-day change | +1.27% | -0.48% |
| YTD return | -20.75% | -31.71% |
| 1-year return | -8.80% | -45.03% |
| 5-year return | -73.31% | -86.77% |
| EPS (TTM) | $-2.82 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.04 | $8.59 |
| 52-week low | $13.46 | $2.74 |
| Distance from 52-week high | -32.07% | -51.34% |
| Analyst consensus | none | hold |
| Avg. price target upside | -9.89% | -6.46% |
| Average volume | 301.04K | 2.04M |
| Shares outstanding | 27.52M | 95.65M |
| Employees | 1,315 | 2,700 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FLGT has outperformed MYGN by 36.2 percentage points over the past year.
About Fulgent Genetics
FLGT stock →Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
Health Care · Medical Specialities · 1,315 employees
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
FLGT vs MYGN FAQ
Which is bigger, Fulgent Genetics or Myriad Genetics?
Fulgent Genetics (FLGT) is larger, with a market capitalization of $580.16M compared with $399.82M for Myriad Genetics (MYGN).
Which stock has performed better over the past year, FLGT or MYGN?
FLGT returned -8.80% over the past 12 months, compared with -45.03% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Fulgent Genetics and Myriad Genetics in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Fulgent Genetics and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Myriad Genetics.